Stock Detail
ANTHERA PHARMACEUTICALS INC
Biotechnology
ANTH @ Yahoo Finance | ANTH Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.81 | $7.06 | $-0.09 | -1.30% | 0.00 | $6.90 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.84 | $6.77 | 109,181 | 278.58M | 100,143 | -3.11 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 7.17 | 6.99 | 6.88 | 6.70 | 6.59 |
Stock Profile
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.